Reduced P-selectin in Hearts Pretreated with Fluvastatin: A Novel Benefit for Patients Undergoing Open Heart Surgery

Abstract

Objective: P-selectin is an adhesion molecule that plays a role in the pathogenesis of atherosclerosis. The aim of this study was to assess whether or not the treatment with fluvastatin for 3 weeks preoperatively would reduce the levels of circulating P-selectin in patients with coronary heart disease undergoing coronary artery bypass grafting surgery (CABG). Materials and Methods: Forty-six patients referred to CABG operation were included in the study. The patients were randomized into two groups (1 : 1): one treated with fluvastatin (80 mg/day, fluvastatin group, n = 23), and the other one treated with placebo (placebo group, n = 23) for three weeks before surgery. All patients underwent CABG using CPB. Blood samples were collected at baseline (the day before surgery), before and after aortic cross-clamping (ACC), at postoperative 0 h (the end of surgical intervention), and at 4, 12, and 24 hours postoperatively. Concentrations of soluble P-selectin (sP-selectin) were analyzed. Results: The sP-selectin values measured in the fluvastatin group were significantly lower than the values measured in the placebo group. There was less use of intraoperative inotropic agents in the fluvastatin group (p < 0.015) and the difference in the length of ICU and hospital stay showed a significantly shorter stay for the fluvastatin group. Conclusions: Pretreatment with fluvastatin seemed to reduce P-selectin levels compared to patients given placebo, and hence, we think that pretreatment with a statin, fluvastatin in our study, might reduce the perioperative cardiac injury caused by cardiopulmonary bypass-induced inflammatory changes. We believe that routine preoperative use of fluvastatin should be carefully considered.

Key words

coronary bypass surgery - myocardial protection - cardiovascular surgery - fluvastatin - sP‐selectin

References

• 1 Seljeflot I, Tonstad S, Hjermann I. et al . Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease.  Atherosclerosis. 2002;  162 179-185
• 2 Jukema J W, Bruschke A VG, van Boven A J. et al . Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).  Circulation. 1995;  91 2528-2540
• 3 Pitt B, Mancini G BJ, Ellis S G. et al . Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC‐1): reduction in atherosclerosis progression and clinical events.  J Am Coll Cardiol. 1995;  26 1133-1139
• 4 Ley K, Tedder T F. Leukocyte interactions with vascular endothelium: new insights into selectin mediated attachment and rolling.  J Immunol. 1995;  155 525-528
• 5 Boldt J, Kumle B, Papsdorf M. et al . Are circulating adhesion molecules specifically changed in cardiac surgical patients?.  Ann Thorac Surg. 1998;  65 608-614
• 6 Kalawski R, Majewski M, Kaszkowiak E. et al . Transcardiac release of soluble adhesion molecules during coronary artery bypass grafting: effects of crystalloid and blood cardioplegia.  Chest. 2003;  123 1355-1360
• 7 Siminiak T, Simielecki J, Dye J F. Detection of soluble adhesion molecules L-selectin and vascular cell adhesion molecule 1 during acute myocardial infarction.  Exp Clin Cardiol. 1997;  2 215-218
• 8 Mizia-Stec K, Zahorska-Markiewicz B, Mandecki T. et al . Serum levels of selected adhesion molecules in patients with coronary artery disease.  Int J Cardiol. 2002;  83 143-150
• 9 Johnson R C, Chapman S M, Dong Z M. et al . Absence of P selectin delays fatty streak formation in mice.  J Clin Invest. 1997;  99 1037-1043
• 10 Collins R G, Velji R, Guevara N V. et al . P selectin or intercellaular adhesion molecule (ICAM)-1 deficiency substantially protects against atherosclerosis in apolipoprotein E deficient mice.  J Exp Med. 2000;  191 189-194
• 11 Blann A D, Seigneur M, Boisseau M R. et al . Soluble P selectin in peripheral vascular disease: relationship to the location and extent of atherosclerotic disease and its risk factors.  Blood Coagul Fibrinolysis. 1996;  7 789-793
• 12 Ikeda H, Takajo Y, Ichiki K. et al . Increased soluble form of P selectin in patients with unstable angina.  Circulation. 1995;  92 1693-1696
• 13 Güray U, Erbay A R, Güray Y, Yilmaz M B, Boyaci A A, Sasmaz H, Korkmaz S, Kütük E. Levels of soluble adhesion molecules in various clinical presentations of coronary atherosclerosis.  Int J Cardiol. 2004;  96 235-240
• 14 Marschang P, Friedrich G J, Ditlbacher H. et al . Reduction of soluble P selectin by statins is inversely correlated with the progression of coronary artery disease.  Int J Cardiol. 2006;  106 183-190
• 15 Byrne J G, Smith W J, Murphy M P. et al . Complete prevention of myocardial stunning, contracture, low-reflow, and edema after heart transplantation by blocking neutrophil adhesion molecules during reperfusion.  J Thorac Cardiovasc Surg. 1992;  104 1589
• 16 Vernier E D, Shen I. Potential role of neutrophil antiadhesion therapy in myocardial stunning, myocardial infarction and organ dysfunction after cardiopulmonary bypass.  J Cardiac Surg. 1993;  8 309-312
• 17 Datani M I, Elnicki M, Jain A C. Effect of preoperative statin therapy and cardiac outcome after coronary artery bypass grafting.  Am J Cardiol. 2000;  86 1128-1130
• 18 Rasmussen L M, Hansen P R, Nabipour M T. Diverse effects of inhibition of 3 hydroxy-3 methylglutaryl CoA reductase on the expression of VCAM‐1 and E selectin in endothelial cells.  Biochem J. 2001;  360 363-370
• 19 Pruefer D, Scalia R, Lefer A M. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats.  Arterioscler Thromb Vasc Biol. 1999;  19 2894-2900
• 20 Kimura M, Kurose I, Russell J. et al . Effects of fluvastatin on leukocyte endothelial cell adhesion in hypercholesterolemic rats.  Arterioscler Thromb Vasc Biol. 1997;  17 11521-11526
• 21 Huhle G, Abletshauser C, Mayer N. et al . Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG‐CoA-reductase inhibitor.  Thromb Res. 1999;  95 229-234
• 22 Gurbel P A, Kereiakes D J, Serebruany V L. Soluble P-selectin is not a surrogate marker for platelet P-selectin: evidence from a multicenter chest pain study group.  J Thromb Thrombolysis. 2000;  10 15-22
• 23 Davi G, Romano M, Mezzetti A. Increased levels of soluble P selectin in hypercholestrolemic patients.  Circulation. 1998;  97 953-957
• 24 Fijnheer R, Frijns J M, Korteweg A. et al . The origin of P selectin as a circulating plasma protein.  Thromb Haemost. 1997;  77 1081-1085